吳立真教授

博士  康乃爾大學  (2000)
博士後研究員 (中央研究院生物醫學科學研究所,2000-2002)
國立暨南國際大學化學系 助理教授 (2002-2006)
國立暨南國際大學化學系 副教授 (2006-2013)
國立暨南國際大學化學系 教授 (2013-現今)

分析化學
1. 生醫分析
2. 晶片電泳
3. 天然物化學
生醫奈米科技
1. 藥物傳遞

Google Scholar:
https://scholar.google.com.tw/citations?user=dkSxKIkAAAAJ&hl=zh-

Selected Publications :
1)   Chang, Y.J., Hsu, S.L., Liu, Y.T., Lin, Y.H., Lin, M.H., Huang, S.J., Ho, J.A., Wu, L.C.* (2015) Gallic acid    induces
      necroptosis via TNF–α signaling pathway in activated hepatic stellate cells.
      PLoS one, 10(3),1-19 (5- Year IF=3.702, 9/57‐Multidiscipliuary Sciences)
2)   Lu, H.-Y., Chang, Y.-J., Fan, N.-C., Wang, L.-S., Lai, N.-C., Yang, C.-M.,* Wu, L.-C.,* Ho, J.-a. A.* (2015)
      Synergism through Combination of Chemotherapy and Oxidative Stress-induced Autophagy in
      A549 Lung Cancer Cells Using Redox-responsive Nanohybrids: A New Strategy for Cancer Therapy,
      Biomaterials, 42(2),30-41. (SCI) (5-Year IF=9.305, 1/33‐ Materials Science, Biomaterials)
3)   Wu, L.C.,* Chu, L.-W., Lo, L.-W., Liao, Y.-C., Wang, Y.-C., Yang, C.-S.* (2013) Programmable Cellular  Retention of
      Nanoparticles by Replacing the Synergistic Anion of Transferrin, ACS nano, 7 (1), 365–375. (5-
      Year IF=14.412, 1/33 ‐ Materials Science, Multidiscipliuary)
4)   Teng, I.-T., Chang, Y.-J., Wang, L.-S., Lu, H.-Y., Wu, L.-C.,* Yang, C.-M.,* Chiu, C.-C., Yang, C.-H., Hsu,
       S.-L., Ho, J.-a. A.* (2013) Phospholipid-functionalized mesoporous silica nanocarriers for selective
       photodynamic therapy of cancer. Biomaterials, 34(30), 7462-7470. (SCI) (5-Year IF=9.305, 1/33‐ Materials
       Science, Biomaterials)
5)   Wu, L.-C.,* Hu, C.-Y., Dung, Y.-S., Wu, T.-H. (2013) In-capillary formation of polymer/surfactant c
      complexes–assisted reversed-migration micellar electrokinetic chromatography for facile analysis of neutral
      steroids, Talanta, 107, 389–395. (5-Year IF=3.670 , 11/74 ‐Chemistry Analytical)
6)   Wu, L.C.,* Lin, Y.Y., Yang, S.Y., Weng, Y.T., Tsai, Y.Y. (2011) Antimelanogenic effect of c-phycocyanin
      through modu- lation of tyrosinase expression by upregulation of ERK and down- regulation of p38 MAPK
      signal- ing pathways. J Biomed Sci. 18, 74-84,(5-Year IF=2.926, 50/123-Medicine, Research and Experimental)